ORGANIGRAM HLDGS I COM NPV (OTCMKTS:OGRMF) showing dropped/jumped of -0.12% and closed at $1.92, after gaining total volume of 0.00 shares. It has total market capitalization of $188.72 million and a total of 98.29 million outstanding shares.

ORGANIGRAM HLDGS I COM NPV (OGRMF) on March 15, 2017 announced that it has issued an aggregate of 1,500,000 incentive stock options to Greg Engel, a director of the Company and the Company’s Chief Executive Officer, at an exercise price of $2.36 per share.

In accordance with Mr. Engel’s employment contract, 266,666 of the Options shall vest on March 13, 2018; 266,667 of the Options shall vest on March 13, 2019; and 266,667 of the Options shall vest on March 13, 2020.

Additionally, 350,000 stock options shall vest upon the common shares of the Company trading at a price at or greater than $4.76/share; and, 350,000 stock options shall vest upon the common shares of the Company trading at a price at or greater than $7.14/share. In each instance, the common shares of the Company must trade at or greater than the price set forth above for a period of not less than 20 consecutive trading days.

All of the above-mentioned options have been granted pursuant to the Company’s Stock Option Plan which has been previously approved by the Company’s shareholders and the TSX Venture Exchange. In accordance with the Plan, all such options shall expire 10 years after issuance.

mCig Inc (OTCMKTS:MCIG) increased -2.16% closed at $0.250 and traded with total volume of 0.00 shares, while the average trading remained 5.26 million shares. During last trade its minimum price was $0.24 and it gained the highest price of $0.26. Its market capitalization was $86.92 million.

mCig Inc (MCIG) on February 1, 2017 announced it has entered into legally binding subscription agreements with Paul Rosenberg, Chairman and Chief Executive Officer and Michael Hawkins, Chief Financial Officer for the issuance of 25,000 newly issued Series A Preferred shares each. Under the agreements Mr. Rosenberg and Mr. Hawkins will subscribe for and purchase directly or through their own beneficially owned and controlled special purpose vehicle 25,000 shares of Series A Preferred stock each for a total purchase price of $200,000 ($100,000 each), or $4.00 per share, which equates to $0.40 per common share in conversion. In addition to the Series A Preferred stock, Mr. Rosenberg and Mr. Hawkins will each receive a five year warrant for an equal amount of common shares at $0.75 per share.

MCIG remains ultra conservative in its financing measures. The Company has a long history of self-supporting its operations and continues to protect its shareholders from a toxic debt strategy. Paul Rosenberg stated, “We will remain diligent in our financing strategies as we continue to expand operations and grow vertically and horizontally.”

Headquartered in Henderson, Nevada, mCig Inc. (MCIG ) is a diversified company servicing the legal cannabis, hemp and CBD markets via its lifestyle brands. MCIG has transitioned from a vaporizer manufacturer to an industry leading large scale, full service cannabis cultivation construction company with its Grow Contractors division currently operating in the rapidly expanding Nevada market. The company looks forward to growing its core competencies to service the Ancillary legal Cannabis, Hemp and CBD markets, with broader expansion to take place once federal laws change. For more information visit www.mcig.org.

Earth Science Tech Inc (OTCMKTS:ETST) reported the surge of 0.62% and closed at $1.62, with the total traded volume of 0.00 shares. During last trade its minimum price was $1.61 and it gained its highest price of $1.68 and has a total of 40.91 million outstanding shares.

On March 6, 2017 Earth Science Tech, Inc. (ETST), an innovative biotech company focused on cannabis (industrial hemp) and cannabinoid research and development, nutraceuticals, pharmaceuticals, and medical devices based company is proud to announce that its wholly owned subsidiary Cannabis Therapeutics timeline for its cannabis cannabinoid-based nutraceutical patent and generic pharmaceutical drug completion.

At a meeting with the company’s Advisory Board on Tuesday, February 28th at Le Centre Québecois d’Innovation en Biotechnologie (CQIB) in Laval, Québec; the scientists concluded that the improved CBD Hemp Oil food supplement was ready to move to prototyping, and then to be fast tracked to commercialization. In addition, two cannabinoid-based generic pharmaceutical drugs will be ready for pre-market clinical trials related to drug bioavailability by Q3 2017. Depending on the time needed to properly conduct the clinical trials, both of the pharmaceutical drugs looks to be completed by the end of 2017 or beginning of 2018.

The first or these two generic drugs, an anti-breast cancer drug, is an important advance for the company as breast cancer affects more women worldwide than any other cancer. The components of the anti-breast cancer drug that Cannabis Therapeutics is bringing to market are contained in the World Health Organization’s current Model List of Essential Medicines (2015). The WHO Model Complementary List indicates the essential medicines needed to treat priority diseases, such as breast cancer, by any healthcare system.